BEDFORD, Mass., Sept. 28, 2009 /PRNewswire-FirstCall/ -- Hologic, Inc. (Hologic or the Company) (NASDAQ: HOLX), a leading developer, manufacturer and supplier of premium diagnostics, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, today announced that Jack Cumming, Hologic Chairman and CEO, will preside over the NASDAQ opening bell ceremony in New York City on Thursday, October 1, 2009 at 9:30 a.m. (EST) for the fourth consecutive year to honor the National Breast Cancer Awareness Month and to kick off Hologic's "Promise to Me" campaign. The initiative is focused on increasing awareness of the importance of breast cancer screening and Hologic's funding of mammograms for underserved women.
The American Cancer Society estimates more than 240,000 new cases of breast cancer are diagnosed in the U.S. each year, with one of eight women being inflicted with this deadly disease in her lifetime.(1) "These statistics are overwhelming and we remain deeply committed to helping women worldwide who are afflicted by this dreadful disease," said Mr. Cumming. "Breast cancer screening programs and technologies, such as digital mammography, have gone a long way toward decreasing death rates from breast cancer and we will continue to do so not only with our current technology, but with the introduction of new technologies such as our 3-D Selenia® Dimensions™ digital tomosynthesis system.(2)"
Hologic is the worldwide leader in digital mammography systems with over 5,000 Selenia systems shipped. Digital mammography has set a new standard for providing the earliest detection of breast cancer and Hologic is proud to be the preferred system of choice around the world.
The focus of the Promise to Me campaign is to empower women to take ownership of their health, starting with scheduling an annual mammogram. Program details will be fully available on October 1, 2009, at www.promisetome.com. Through this initiative, Hologic has committed to support women who are unable to afford mammograms, and the Company has done so through a partnership with Remote Area Medical (RAM), a non-profit, volunteer organization dedicated to bringing healthcare services to underserved populations in remote areas in the U.S. and abroad.
"Hologic's focus and concentration on breast cancer is unparalleled," Mr. Cumming said. "No other major healthcare company devotes a higher percentage of its resources to the development and deployment of screening, diagnostic and therapeutic technologies to meet the diverse challenges of this disease. As a result, breast surgeons, radiation oncologists, and related healthcare professionals have come to rely on Hologic's continued advancements in digital mammography, biopsy technologies, and radiation-focused breast conservation therapy. Early detection can significantly improve a woman's chance of surviving breast cancer and we remain passionately committed to improving women's healthcare by providing a comprehensive portfolio of tools and innovations to aid in early detection. It is our hope that increased awareness will encourage more women to include screening mammography as part of their routine medical care."
To view the NASDAQ opening bell ceremony on October 1st, 2009, visit www.nasdaq.com/reference/marketsite_about.stm beginning at 9:15 a.m. (EST). Viewers must have Windows Media Player to view the web cam. Scroll to the bottom of the page under the heading MarketSite Live Web cam and click on Windows Media Player. The Web cam is live only and is not archived. Jack Cumming's opening remarks will also be available on the investor relations page of the Company's website at www.hologic.com/investor.
Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women. Hologic's core business units are focused on breast health, diagnostics, GYN surgical, and skeletal health. Hologic provides a comprehensive suite of technologies with products for mammography and breast biopsy, radiation treatment for early-stage breast cancer, cervical cancer screening, treatment for menorrhagia, permanent contraception, osteoporosis assessment, preterm birth risk assessment, mini C-arm for extremity imaging and molecular diagnostic products including HPV and reagents for a variety of DNA and RNA analysis applications.
Forward Looking Statement Disclaimer
This News Release may contain forward-looking information that involves risks and uncertainties, including statements about the use of digital mammography and digital breast tomosynthesis. There can be no assurance that these systems will achieve the benefits described herein and that such benefits will be replicated in any particular manner with respect to an individual patient as the actual effects of the use of these systems can only be determined on a case-by-case basis depending on the particular circumstances of the procedure and patient in question. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to the data or statements presented herein to reflect any change in the Company's expectations or any change in events, conditions or circumstances on which any such data or statements are based. Certain factors that could adversely affect the Company's business and prospects are described in Hologic filings with the Securities and Exchange Commission.
Hologic, Selenia, and Dimensions are trademarks and/or registered trademarks of Hologic, Inc., and/or its subsidiaries in the United States and/or other countries.
(1) American Cancer Society, Breast Cancer Facts and Figures: 2007-2008.
(2) Hologic's Selenia Dimensions 3-D digital tomosynthesis system is approved for use in Europe, Canada and other countries and awaiting FDA approval in the United States.
Deborah R. Gordon
Vice President, Investor Relations